Your session is about to expire
← Back to Search
Lung Cancer Vaccine for Lung Cancer Prevention and Recurrence
Study Summary
This trial is testing a vaccine to prevent lung cancer in patients who are at high risk for the disease or in stage IB-IIIA non-small cell lung cancer survivors to see if it is effective and has minimal side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am at high risk for lung cancer due to factors like COPD, family history, low BMI, recent pneumonia, occupational exposure, or smoking history.You must have enough platelets in your blood (at least 100 billion per liter).It is not safe for me to undergo a bronchoscopy.I have a condition that weakens my immune system, like HIV.I had lung cancer surgery or treatment over 3 months ago, initially diagnosed at stage IA-3A.I am an adult capable of making decisions, not pregnant, and not incarcerated.I can take care of myself and am up and about more than half of my waking hours.My recent CT scan showed no signs of cancer.I have an autoimmune disorder but it's either vitiligo or an endocrine issue treated with hormones.I do not have any uncontrolled illnesses that could interfere with the study.
- Group 1: Prevention (recombinant human EGF-rP64K/montanide ISA 51)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the customary application of Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine?
"Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine is an effective remedy when it comes to second degree burns and other issues such as wounds, ulcers or organ transplantation."
Do I meet the requirements to join this research endeavor?
"The current trial is recruiting 60 elderly patients (ages 50-79) afflicted with pneumonia. To qualify, applicants must have platelet counts of at least 100 x 10^9/L, understand the research nature of this study and sign a written informed consent form prior to any procedures, display no evidence of cancer on their CT scan within 6 months before treatment begins, possess an ECOG performance status =< 2, women capable of pregnancy should commit to using adequate contraceptive methods for contraception or abstinence during participation in this study; if pregnant while involved any suspected pregnancies should be reported immediately to treating physicians. Furthermore individuals partaking in Cohort A who"
What is the aggregate number of participants in this research endeavor?
"Affirmative. According to clinicaltrials.gov, this medical research project is currently recruiting participants - it was initially posted on November 22nd 2021 and has been periodically updated since then with the latest update being October 20th 2022. The trial requires 60 individuals from 1 centre for successful completion."
Does this trial permit enrollees who are octogenarians?
"This medical trial is limited to adults aged 50 to 79. There are 246 studies for participants younger than 18 years old and an additional 3381 trials suitable for those over the age of 65."
Is enrollment still available for this trial?
"Affirmative. Clinicaltrials.gov reveals that, since its initial posting on November 22nd 2021, this trial is actively recruiting patients. 60 participants are required from 1 clinical site for the study to be successful."
Has this research endeavor been attempted before?
"Currently, 5 ongoing clinical trials are being conducted for Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine in 9 cities across two nations. The inaugural investigation of this drug was sponsored by Boehringer Ingelheim and involved 50 trialists completing Phase 2 approval back in 2015 - an event which has since been followed up with 235 further studies."
Has there ever been a study of the effects of Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine on humans?
"Presently, 5 studies of the Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine are ongoing with one trial in Phase 3. While Shenyang, Liaoning is hosting a significant amount of them, there are 10 research centers total that have trials open for this vaccine."
Share this study with friends
Copy Link
Messenger